Monoclonal antibody binding specifically to DLL4 and use thereof
US9598483B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 2, 2013 |
| Grant date | Mar 21, 2017 |
| Priority date | — |
| Expiry date | Oct 15, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/4703
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a novel monoclonal antibody that binds specifically to delta-like ligand (DLL4), and more particularly to a monoclonal antibody that binds specifically to human delta-like ligand 4 to effectively inhibit the interaction between delta-like ligand 4 and Notch receptor, a polynucleotide encoding the monoclonal antibody, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the monoclonal antibody, a pharmaceutical composition for preventing or treating cancer comprising the monoclonal antibody, a composition for diagnosing cancer comprising the monoclonal antibody, a method for diagnosing cancer using the monoclonal antibody, and a pharmaceutical composition for preventing or treating autoimmune disease comprising the monoclonal antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.